Search
Lutein
go.drugbank.com/drugs/DB00137ApprovedNutraceuticalLutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots. … In green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very
Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.
Selenomethionine
go.drugbank.com/drugs/DB11142ApprovedInvestigationalSelenomethionine is a naturally occuring amino acid in some plant materials such as cereal grains, soybeans and enriched yeast but it cannot be synthesized from animals or humans. … It can be produced from post-structural modifications.
Dobutamine
go.drugbank.com/drugs/DB00841ApprovedInvestigationalA beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Synonyms: 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamineEftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedWhen untreated, most patients die from bleeding complications before 25 years of age [A31557]. … Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.
Eravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive
Bromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnBromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesi...
Mixtures: Pred-Brom, Pred-BromNatalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigational[L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.
Benserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalA decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … of dopamine from levadopa in extracerebral tissues - thereby acting to minimize the occurrence of extracerebral side effects [F2, L2553].
Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigational[A31290] Letermovir has recieved both priority and orphan drug status from the FDA. It is currently marketed under the brand name Prevymis.[L1021] … Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.